<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02561299</url>
  </required_header>
  <id_info>
    <org_study_id>CLN-0007-P</org_study_id>
    <nct_id>NCT02561299</nct_id>
  </id_info>
  <brief_title>Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study</brief_title>
  <acronym>OPTIMIZE BTK</acronym>
  <official_title>Orbital Vessel PreparaTIon to MaximIZe Dcb Efficacy in Calcified Below the Knee (BTK) Lesions - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardiovascular Systems Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cardiovascular Systems Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to prospectively evaluate acute and long term clinical results
      of orbital atherectomy (OA) with adjunctive drug coated balloon (DCB) angioplasty versus DCB
      angioplasty alone for treatment of Peripheral Artery Disease (PAD) in below the knee (BTK)
      lesions.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success (per lesion), defined as final residual stenosis post DCB angioplasty &lt; 50 % via angiography without significant angiographic complications</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Technical success (per lesion), defined as final residual stenosis post DCB angioplasty &lt; 50 % via angiography without significant angiographic complications (perforation, distal embolization, dissection types C-F, slow flow/no reflow) during the index procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural success (per subject), defined as achievement of technical success for all target lesions treated</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Procedural success (per subject), defined as achievement of technical success for all target lesions treated during the index procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device success (per each DCB used during the index procedure), defined as the ability to achieve successful delivery and deployment of the DCB to the target lesion as described per Instructions for Use (IFU)</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Device success (per each DCB used during the index procedure), defined as the ability to achieve successful delivery and deployment of the DCB to the target lesion as described per Instructions for Use (IFU) within 3 minutes of insertion without removal and use of an additional device</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success (per lesion), defined as the percentage of target lesions meeting technical success with &lt; 30 % final residual stenosis post DCB angioplasty</measure>
    <time_frame>Index Procedure</time_frame>
    <description>Treatment success (per lesion), defined as the percentage of target lesions meeting technical success with &lt; 30 % final residual stenosis post DCB angioplasty without the use of alternative or post-adjunctive treatments during the index procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Lumen Loss (LLL) of the target lesion by Quantitative Vascular Angiography (QVA)</measure>
    <time_frame>6 Month</time_frame>
    <description>Late Lumen Loss (LLL) of the target lesion by Quantitative Vascular Angiography (QVA) at 6 months post-procedure or at the time of Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency of the target lesion by Duplex Ultrasound (DUS) post-procedure</measure>
    <time_frame>6 Month and 12 Month</time_frame>
    <description>Patency of the target lesion by Duplex Ultrasound (DUS) at 6 months and 12 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Major Adverse Events (MAEs) post-procedure</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Freedom from Major Adverse Events (MAEs) at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure. MAEs include: clinically driven TLR; unplanned, unavoidable major amputation of the index limb; and death within 30 days of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from clinically driven target lesion revascularization</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Freedom from clinically driven target lesion revascularization at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from unplanned, unavoidable major amputation of the index limb</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Freedom from unplanned, unavoidable major amputation of the index limb at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rutherford Category</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Change in Rutherford Category at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic outcome (Ankle-Brachial Index and Toe-Brachial Index)</measure>
    <time_frame>3 Month, 6 Month, 12 Month</time_frame>
    <description>Hemodynamic outcome (ABI and TBI) at 3 months, 6 months, and 12 months post-procedure compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QoL)</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Change in quality of life (QoL) at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure from baseline assessed by EuroQoL Quality of Life Questionnaire (EQ-5D)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in walking capacity</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Change in walking capacity at 30 days, 3 months, 6 months, 12 months, and 24 months post-procedure from baseline assessed by Walking Impairment Questionnaire (WIQ)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the EQ-5D-5L questionnaire</measure>
    <time_frame>30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>EQ-5D summary scores (min value 0, max value 1), in conjunction with mortality data, will be used to compute quality adjusted life years (QALY) for further health-economic analyses. The QALY results will be compared between treatment arms at various time points during follow-up at 30 days, 3 months, 6 months, 12 months, and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related costs</measure>
    <time_frame>Index Procedure, 30 Day, 3 Month, 6 Month, 12 Month, 24 Month</time_frame>
    <description>Inpatient cost and reimbursement data will be obtained from participating hospitals, and compared between treatment arms at various time points during follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>PAD</condition>
  <condition>Vascular Calcification</condition>
  <arm_group>
    <arm_group_label>OA with adjunctive DCB angioplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lesion preparation with Peripheral Orbital Atherectomy System followed by drug-coated balloon angioplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCB angioplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>014 Drug Coated Balloon angioplasty</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral Orbital Atherectomy System</intervention_name>
    <description>Orbital Atherectomy</description>
    <arm_group_label>OA with adjunctive DCB angioplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>014 Drug Coated Balloon</intervention_name>
    <description>Drug Coated Balloon</description>
    <arm_group_label>OA with adjunctive DCB angioplasty</arm_group_label>
    <arm_group_label>DCB angioplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject's age ≥ 18 years

          -  Rutherford Clinical Category 3 - 5

          -  Lesions [except in-stent restenosis (ISR)] of the distal popliteal (POP segment below
             the anatomical knee joint), anterior tibial, posterior tibial, tibial peroneal trunk,
             and peroneal arteries with ≥ 70 % diameter stenosis (DS) by angiography

          -  Presence of clearly visible calcification in two views (both sides of vessel at the
             same location) evaluated angiographically- [Computerized tomography (CT) angio images
             may substitute to confirm distribution of calcium, if available as standard of care]

          -  Length of calcium ≥ 25 % of total lesion length or ≥ 2 cm total length

          -  Target lesion length up to 20 cm

        Exclusion Criteria:

          -  Subject or subject's legal representative is not willing to sign an Ethics Committee
             approved informed consent form or comply with the study protocol requirements

          -  Contraindicated by either device, per Instructions For Use

          -  Presence of inflow lesion (≥ 50 % DS) or inflow not successfully treated (≥ 50% DS
             and/or unresolved significant angiographic complication)

          -  Compromised outflow distal to the target lesion (≥ 70 % DS) or presence of lesion(s)
             or occlusion(s) located from 5 cm above the ankle to below the ankle joint space

          -  Subject has more than 2 target vessels requiring treatment

          -  The guide wire cannot be passed across the target lesion(s) and/or guide wire position
             distal to target lesion(s) outside vessel lumen

          -  Presence of significant (≥ 70 % DS) lesion(s) or occlusion(s) not meeting the study
             criteria which were not successfully treated during the index procedure (≥ 50 % DS
             and/or significant angiographic complication)

          -  Subject has planned amputation (including minor) of the index limb or previous major
             amputation of the contralateral limb

          -  Creatinine &gt; 2.5 mg/dL, unless on dialysis

          -  Subject has any significant medical condition which, in the Investigator's opinion,
             may interfere with the subject's optimal participation in the study

          -  Subject is participating in an investigational drug or device study that has the
             potential to clinically interfere with the study outcome measures

          -  Subject is pregnant or planning to become pregnant within the study period

          -  Subject has an unresolved severe systemic infection

          -  Subject has an anticipated life span of less than one year

          -  Subjects with known hypersensitivity to paclitaxel or paclitaxel related compounds

          -  Subjects who cannot receive recommended anti-platelet and/or anticoagulant therapy

          -  Pre-dilatation of the target lesion prior to randomization and OA treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Marianne Brodmann, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Graz, Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Gunnar Tepe, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Rosenheim Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Professor Thomas Zeller, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Herz-Zentrum Bad Krozingen Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marcy Weatherspoon</last_name>
    <phone>612-850-5181</phone>
    <email>mweatherspoon@csi360.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. Marianne Brodmann</last_name>
      <phone>0043 316 385 80286</phone>
      <email>marianne.brodmann@medunigraz.at</email>
    </contact>
    <contact_backup>
      <last_name>Prof. Dr. Hannes Deutschmann</last_name>
      <phone>0043 316 385 13271</phone>
      <email>hannes.deutschmann@klinikum-graz.at</email>
    </contact_backup>
    <investigator>
      <last_name>Prof. Dr. Marianne Brodmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vascular Clinic - Hanusch Hospital</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priv.-Doz. Dr. Martin Werner</last_name>
      <phone>01/91021/86111</phone>
      <email>martin.werner@wgkk.at</email>
    </contact>
    <investigator>
      <last_name>Priv.-Doz. Dr. Martin Werner</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitäts-Herzzentrum Freiburg - Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med. Thomas Zeller</last_name>
      <phone>+49 7633 402-2431</phone>
      <email>thomas.zeller@universitaets-herzzentrum.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Dr. med. Thomas Zeller</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fürst-Strium-Klinik Bruchsal</name>
      <address>
        <city>Bruchsal</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med Martin Andrassy</last_name>
      <phone>+49-7251-708-57791</phone>
      <email>martin.andrassy@kliniken-lk.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SRH Klinikum Karlsbad- Langensteinbach GmbH</name>
      <address>
        <city>Karlsbad</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med Erwin Blessing</last_name>
      <phone>+49 7202 61 3340</phone>
      <email>Erwin.Blessing@kkl.srh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universität Leipzig</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med Dierk Scheinert</last_name>
      <phone>+ 49 341 9718770</phone>
      <email>Dierk.Scheinert@medizin.uni-leipzig.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Romed Klinikum Rosenheim</name>
      <address>
        <city>Rosenheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Dr. med. Gunnar Tepe</last_name>
      <phone>+49 (0) 8031-365 3550</phone>
      <email>gunnar.tepe@ro-med.de</email>
    </contact>
    <investigator>
      <last_name>Prof. Dr. med. Gunnar Tepe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lucerne Cantonal Hospital</name>
      <address>
        <city>Lucerne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr. Martin Banyai</last_name>
      <phone>041 205 52 09</phone>
      <email>martin.banyai@luks.ch</email>
    </contact>
    <investigator>
      <last_name>Dr. Martin Banyai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>September 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2015</study_first_posted>
  <last_update_submitted>June 8, 2017</last_update_submitted>
  <last_update_submitted_qc>June 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-coated Balloons</keyword>
  <keyword>Calcified Lesions</keyword>
  <keyword>Orbital Atherectomy</keyword>
  <keyword>Below the Knee</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Lutonix 014 Drug-coated Balloon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
    <mesh_term>Vascular Calcification</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

